Get the Stockscreener App
83.10
0.88%
-0.74
After Hours:
83.10
Edwards Lifesciences Corp stock is traded at $83.10, with a volume of 6.29M.
It is down -0.88% in the last 24 hours and up +0.02% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$83.84
Open:
$83.32
24h Volume:
6.29M
Relative Volume:
1.59
Market Cap:
$48.22B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
35.38
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
-2.04%
1M Performance:
+0.02%
6M Performance:
+6.16%
1Y Performance:
+16.98%
1-Day Range:
$81.26
$83.60
1-Week Range:
$81.26
$86.10
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
83.10 | 48.65B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
125.00 | 216.14B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
93.74 | 139.56B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
359.39 | 136.07B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.74 | 123.61B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences (EW) Valuation Check As Recent Share Momentum Meets Premium P/E Pricing - Yahoo Finance
Risk Report: Does Edwards Lifesciences Corporation align with a passive investing strategy2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
JPM26: Edwards Lifesciences targets 10% growth in 2026 - Yahoo Finance
What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report - Yahoo Finance
Spire Wealth Management Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Revises Edwards Lifesciences (EW) Price Target and Maintains Neutral Rating | EW Stock News - GuruFocus
Barclays Raises Price Target for Edwards Lifesciences (EW) to $1 - GuruFocus
FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - Orange County Business Journal
Edwards scraps Jenavalve buy in face of FTC objections - BioWorld MedTech
Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve - Benzinga
Edwards Lifesciences (EW) Faces Legal Setback in Acquisition Pla - GuruFocus
Edwards Lifesciences Corp Acquisition Blocked by FTC - TradingView — Track All Markets
Hardman Johnston Global Advisors LLC Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Drops Bid to Acquire JenaValve Technology - marketscreener.com
Parnassus Investments LLC Takes $36.93 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Explores Personalized Blood Pressure Targets in New Study - MSN
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Bitget
Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $87,328.30 in Stock - MarketBeat
Edwards Lifesciences (EW) Updates Earnings Guidance for 2023 - GuruFocus
US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Reuters
Edwards says co will not acquire Jenavalve - marketscreener.com
Edwards Comments on JenaValve Acquisition - FinancialContent
Court sides with FTC to put Edwards Lifesciences’ JenaValve acquisition on hold - MassDevice
Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares - Stock Titan
US FTC wins ruling blocking Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Judge Blocks Edwards' $945M Heart Valve Deal - Law360
FTC wins ruling blocking Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
US FTC Wins Ruling Blocking Edwards Lifesciences' Acquisition of JenaValve - US News Money
Judge grants U.S. Federal Trade Commission request to block Edwards Lifesciences Corp's acquisition of Jenavalve Technology Inc -- court records - marketscreener.com
TD Cowen Upgrades Edwards Lifesciences (EW) with a Price Target Boost | EW Stock News - GuruFocus
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $108 From $104, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences stock rating upgraded to Buy by TD Cowen on TAVR growth - Investing.com
Is Edwards Lifesciences Corporation stock gaining market share2025 Growth vs Value & Fast Moving Stock Watchlists - Улправда
Edwards Lifesciences Corporation $EW Shares Purchased by SG Americas Securities LLC - MarketBeat
KLP Kapitalforvaltning AS Boosts Position in Edwards Lifesciences Corporation $EW - MarketBeat
Robeco Institutional Asset Management B.V. Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Investing in Edwards Lifesciences (NYSE:EW) a year ago would have delivered you a 14% gain - Yahoo Finance
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Stifel Nicolaus Increases Edwards Lifesciences (NYSE:EW) Price Target to $105.00 - MarketBeat
Stifel Maintains Buy on Edwards Lifesciences (EW) and Raises Pri - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $105 on growth outlook - Investing.com
Donald Bobo Jr Sells 11,340 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences Officer Sells Over $970K in Company Stock - TradingView — Track All Markets
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Edwards Lifesciences (EW) insider files to sell 45,360 shares under Rule 144 - Stock Titan
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends - simplywall.st
Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One UK Ltd Buys 969,030 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):